Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry
Launched by ETHICON, INC. · Mar 31, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry is a study designed to evaluate how well certain surgical products work for women with stress urinary incontinence (SUI) and pelvic organ prolapse (POP). Specifically, the trial is looking at the performance of mesh products used during surgery to help correct these conditions. If you are a woman aged 21 or older, have symptoms of SUI or POP, and are planning to have surgery using a specific type of synthetic mesh, you may be eligible to participate.
Participants in this trial can expect to undergo standard surgical procedures and will need to agree to follow-up visits to monitor their progress. It’s important to know that certain conditions, such as having had previous pelvic surgeries or being pregnant, would make someone ineligible for the study. The goal of this registry is to gather information that may help improve future treatments for SUI and POP, ultimately benefiting many women facing these issues.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- Patients who satisfy all of the following criteria will be considered eligible for enrollment in this registry:
- • SUI
- • 1. Stress urinary incontinence symptoms
- • 2. Urodynamic stress incontinence confirmed with urodynamic testing
- • 3. Female patient ≥ 21 years of age
- • 4. Desired surgical correction of SUI using synthetic pubo-urethral vaginal sling
- • 5. Planned surgery for primary SUI
- • 6. Patient able and willing to participate in follow-up
- • 7. Patient or authorized representative has signed the approved Informed consent POP
- • 1. Uterine or vaginal vault prolapse symptoms 2. Urodynamic testing (optional) 3. Female patient ≥ 21 years of age 4. Desired surgical correction of POP using synthetic mesh 5. Planned surgery for uterine or vaginal vault prolapse with or without concomitant SUI surgery 6. Patient able and willing to participate in follow-up 7. Patient or authorized representative has signed the approved Informed consent
- • Exclusion Criteria
- Patients meeting any of the following criteria will be considered not eligible for enrollment in this registry:
- • 1. Physical or psychological condition which would impair registry participation or are unwilling or unable to participate in all required registry visits and are unable to complete the questionnaires
- • 2. Any pre-operative or intra-operative findings identified by the surgeon that may preclude the use of registry products
- • 3. History of previous synthetic, biologic or fascial sub-urethral sling (SUI) or pelvic mesh (POP)
- • 4. Pregnancy or plans for future pregnancy
- • 5. History of bleeding diathesis or current anti-coagulation therapy which cannot be suspended peri-operatively according to site's standard practice
- • 6. Current genitourinary fistula or urethral diverticulum
- • 7. Reversible cause of incontinence (i.e. drug effect) for SUI only
- • 8. Severe vaginal atrophy
- • 9. History of pelvic irradiation therapy
- • 10. Contraindication to surgery
About Ethicon, Inc.
Ethicon, Inc., a subsidiary of Johnson & Johnson, is a leading global innovator in surgical products and technologies, dedicated to advancing surgical care through research and development. With a focus on enhancing patient outcomes, Ethicon specializes in the design and manufacturing of sutures, staplers, and minimally invasive surgical instruments, as well as wound care solutions. The company is committed to conducting clinical trials that evaluate the safety and efficacy of its products, ensuring adherence to the highest standards of quality and regulatory compliance. Ethicon's ongoing collaboration with healthcare professionals and institutions aims to drive medical breakthroughs and improve the overall effectiveness of surgical procedures.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Durham, North Carolina, United States
New Haven, Connecticut, United States
Stockholm, , Sweden
Pittsburgh, Pennsylvania, United States
Clermont Ferrand, , France
Prague, , Czechia
Tubingen, , Germany
Linz, , Austria
Hillerod, , Denmark
Lille, , France
Warsaw, , Poland
Rome, , Italy
Patients applied
Trial Officials
Martin Weisberg, MD
Study Director
Ethicon, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials